Johnson & Johnson announces an important finding in the fight against COVID-19! As a result of its efforts in pharmaceutical research and innovation, this company announced that it will begin the phase of human clinical studies at the latest by September 2020.
This good news would mean an achievement in vaccine development, compared to the typical timeframe in the vaccine development process.
If everything goes as expected, the first batches could see the lights in early 2021.
“The world is facing an urgent public health crisis and we are committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible,” said Alex Gorsky, Chairman and CEO, Johnson & Johnson.
In record time, the industry has managed to face the difficulties caused by the pandemic, where the joint efforts of different teams and knowledge has been fundamental to get more closer to effective and stable treatment, and thus recover normality in the world.